Memantine Merz

Memantine, the active ingredient in Memantine Merz, is a NMDA receptor antagonist presented as a unknown/unknown for oral use. It treats moderate to severe Alzheimer’s disease in adults.

GNH USA supplies Memantine Merz as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine is an NMDA receptor antagonist used in the symptomatic treatment of Alzheimer’s disease.

- Moderate to severe Alzheimer’s disease: improves cognition, functional abilities and behavioral symptoms in affected patients. - Mild‑to‑moderate Alzheimer’s disease (off‑label): may provide modest symptomatic benefit. - Dementia associated with Alzheimer’s disease: helps stabilize cognitive decline and daily functioning.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: transient disorientation. - Fatigue: feeling unusually tired. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Cardiac arrhythmia: irregular heart rhythms. - Stevens‑Johnson syndrome: severe skin reaction with blistering. - Hepatic dysfunction: abnormal liver enzyme elevations. - Severe skin reactions: rash, erythema, or exfoliative dermatitis. - Suicidal thoughts: emergence of suicidal ideation or behavior.

Memantine should be used with caution in specific clinical situations. - Renal impairment: dose adjustment may be required based on kidney function. - History of seizures: monitor closely for increased seizure activity. - Cardiovascular disease: assess blood pressure regularly during therapy. - Concurrent use of other NMDA antagonists: avoid duplication to prevent excess CNS depression. - Pregnancy and lactation: safety not established; prescribe only if potential benefit outweighs risk. - Store at room temperature: keep in the original container, protect from moisture and light.

Memantine may interact with several medicines; monitoring is advised.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Other NMDA antagonists (e.g., ketamine): risk of severe central nervous system depression. - Strong CYP450 inducers (e.g., carbamazepine, rifampicin): may reduce memantine plasma concentrations. - High‑dose anticholinergics: may exacerbate cognitive impairment. - Alcohol: can intensify dizziness and confusion.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may increase risk of hypotension. - Antihypertensives: additive blood‑pressure‑lowering effect. - Anticholinergic agents: may counteract memantine’s cognitive benefits. - CNS depressants (e.g., benzodiazepines): enhanced sedation and drowsiness. - Vaccines: monitor immune response, although no direct pharmacokinetic interaction is known.